

Multicenter Evaluation of MIC Distributions for Epidemiologic Cutoff Value Definition To Detect Amphotericin B, Posaconazole, and Itraconazole Resistance among the Most Clinically Relevant Species of *Mucorales*

A. Espinel-Ingroff,^a A. Chakrabarti,^b A. Chowdhary,^c S. Cordoba,^d E. Dannaoui,^e P. Dufresne,^f A. Fothergill,^g M. Ghannoum,^h G. M. Gonzalez,ⁱ J. Guarro,^j S. Kidd,^k C. Lass-Flörl,^l J. F. Meis,^m T. Pelaez,ⁿ A. M. Tortorano,^o J. Turnidge^p

VCU Medical Center, Richmond, Virginia, USA^a; Department of Medical Microbiology, Postgraduate Institute of Medical Education and Research, Chandigarh, India^b; Vallabhbhai Patel Chest Institute, University of Delhi, Delhi, India^c; Instituto Nacional de Enfermedades Infecciosas Dr. C. G. Malbrán, Buenos Aires, Argentina^d; Université Paris-Descartes, Faculté de Médecine, APHP, Hôpital Européen Georges Pompidou, Unité de Parasitologie-Mycologie, Service de Microbiologie, Paris, France^e; Institut National de Santé Publique du Québec, Laboratoire de Santé Publique du Québec, Sainte-Anne-de-Bellevue, Québec, Canada^f; University of Texas Health Science Center, San Antonio, Texas, USA^g; University Hospitals Case Medical Center and Case Western Reserve University, Cleveland, Ohio, USA^h; Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Méxicoⁱ; Facultat de Medicina, IISPV, URV, Reus, Spain^j; National Mycology Reference Centre, SA Pathology, Adelaide, Australia^k; The Innsbruck Medical University, Innsbruck, Austria^l; Department of Medical Microbiology and Infectious Diseases, Canisius Wilhelmina Hospital and Radboud University Medical Center, Nijmegen, The Netherlands^m; Hospital General Universitario Gregorio Marañón, School of Medicine-Universidad Complutense, Madrid, Spainⁿ; Department of Biomedical Sciences for Health, Università degli Studi di Milano, Milan, Italy^o; University of Adelaide, Adelaide, Australia^p

Clinical breakpoints (CBPs) have not been established for the *Mucorales* and any antifungal agent. In lieu of CBPs, epidemiologic cutoff values (ECVs) are proposed for amphotericin B, posaconazole, and itraconazole and four *Mucorales* species. Wild-type (WT) MIC distributions (organisms in a species-drug combination with no detectable acquired resistance mechanisms) were defined with available pooled CLSI MICs from 14 laboratories (Argentina, Australia, Canada, Europe, India, Mexico, and the United States) as follows: 10 *Apophysomyces variabilis*, 32 *Cunninghamella bertholletiae*, 136 *Lichtheimia corymbifera*, 10 *Mucor indicus*, 123 *M. circinelloides*, 19 *M. ramosissimus*, 349 *Rhizopus arrhizus*, 146 *R. microsporus*, 33 *Rhizomucor pusillus*, and 36 *Syncephalastrum racemosum* isolates. CLSI broth microdilution MICs were aggregated for the analyses. ECVs comprising $\geq 95\%$ and $\geq 97.5\%$ of the modeled populations were as follows: amphotericin B ECVs for *L. corymbifera* were 1 and 2 $\mu\text{g/ml}$, those for *M. circinelloides* were 1 and 2 $\mu\text{g/ml}$, those for *R. arrhizus* were 2 and 4 $\mu\text{g/ml}$, and those for *R. microsporus* were 2 and 2 $\mu\text{g/ml}$, respectively; posaconazole ECVs for *L. corymbifera* were 1 and 2, those for *M. circinelloides* were 4 and 4, those for *R. arrhizus* were 1 and 2, and those for *R. microsporus* were 1 and 2, respectively; both itraconazole ECVs for *R. arrhizus* were 2 $\mu\text{g/ml}$. ECVs may aid in detecting emerging resistance or isolates with reduced susceptibility (non-WT MICs) to the agents evaluated.

Although infections caused by filamentous fungi (molds) are not as prevalent as yeast infections, an increased incidence of systemic infections caused by *Aspergillus* and other mold species and more recently by members of the *Mucorales* (*Zygomycetes*) has been documented (1–3). The order *Mucorales* comprises a vast variety of genera and species which have been recently reclassified according to DNA barcoding and internal transcribed spacer (ITS) ribosomal sequencing (4). Although most *Mucorales* species are saprophytic, a large number of these species have been known to cause severe infections (mucormycosis, previously described as zygomycosis), especially among immunocompromised patients and/or patients with granulocytopenia, diabetes, and penetrating trauma (5–7). The recommended therapy for infections caused by the *Mucorales* is usually surgery and/or one of the amphotericin B lipid formulations; despite its toxicity, amphotericin B deoxycholate continues to be used routinely in some areas (5, 8). More recently, posaconazole has been recommended as salvage therapy and/or prophylaxis (9–11); itraconazole and other triazoles are also used as prophylactics (9). Despite antifungal therapy, mucormycosis is associated with a great deal of morbidity and about a 50% mortality rate; breakthrough infections caused by *Mucorales* species among patients receiving triazole prophylaxis, especially voriconazole, are frequently reported (3, 6).

The Clinical and Laboratory Standards Institute (CLSI) Subcommittee on Antifungal Susceptibility Tests has developed a reproducible procedure for the antifungal susceptibility testing of *Mucorales* species as described in the M38-A2 broth microdilution document (12). However, although species-specific formal clinical breakpoints (CBPs) and/or epidemiological cutoff values (ECVs) have been established for *Candida* spp. and *Aspergillus* spp. (13–16), neither MIC distributions nor ECVs are available for

Received 30 September 2014 Returned for modification 20 November 2014
Accepted 4 January 2015

Accepted manuscript posted online 12 January 2015

Citation Espinel-Ingroff A, Chakrabarti A, Chowdhary A, Cordoba S, Dannaoui E, Dufresne P, Fothergill A, Ghannoum M, Gonzalez GM, Guarro J, Kidd S, Lass-Flörl C, Meis JF, Pelaez T, Tortorano AM, Turnidge J. 2015. Multicenter evaluation of MIC distributions for epidemiologic cutoff value definition to detect amphotericin B, posaconazole, and itraconazole resistance among the most clinically relevant species of *Mucorales*. *Antimicrob Agents Chemother* 59:1745–1750.
doi:10.1128/AAC.04435-14.

Address correspondence to A. Espinel-Ingroff, avingrof@vcu.edu.

Copyright © 2015, American Society for Microbiology. All Rights Reserved.

doi:10.1128/AAC.04435-14

TABLE 1 MIC distributions of amphotericin B for 10 *Mucorales* species from 3 to 13 laboratories, determined by using the CLSI M38-A2 microdilution method

Species	No. of isolates tested/no. of labs	No. of isolates with MIC ($\mu\text{g/ml}$) of ^a :										
		≤ 0.03	0.06	0.125	0.25	0.5	1.0	2.0	4.0	8.0	16	32
<i>A. variabilis</i>	10/3		1		1		3	5				
<i>C. bertholletiae</i>	32/6				1	1	5	16	8	1		
<i>L. corymbifera</i>	136/12		7	17	36	53	19	3			1	
<i>M. circinelloides</i>	123/13	1	4	14	42	44	18					
<i>M. indicus</i>	10/5	1		3	4	1	1					
<i>M. ramosissimus</i>	19/5		2	4	3	6	1		1			
<i>R. arrhizus</i>	257/12	1	3	9	26	64	112	39	3			
<i>R. pusillus</i>	33/9		2	6	9	12	1	2		1		
<i>R. microsporus</i>	146/10		2	11	15	62	38	15	3			
<i>S. racemosum</i>	35/5	8	16	3	6	2						

^a The highest number in each row (showing the most frequently obtained MIC or mode) is in boldface.

any *Mucorales* species. The establishment of CBPs for mold species has been hampered by the low incidence of these infections and the scarcity of the data required for their development, including both low and high MICs that might predict clinical failure. However, ECVs are calculated based on MIC distributions (>100 MICs/species/agent) from multiple independent laboratories (≥ 3) (14, 16, 17). Although amphotericin B and triazole MIC data have been reported for a variety of genera belonging to the *Mucorales*, available data are mostly for the more prevalent species, and the number of isolates evaluated is small (18–22).

The purpose of the study was (i) to define wild-type (WT) susceptibility endpoint MIC distributions of 10 *Mucorales* species using CLSI M38-A2 broth microdilution MIC data originating from 3 to 14 laboratories and (ii) to propose ECVs for amphotericin B, posaconazole, and itraconazole for four common *Mucorales* species (*Lichtheimia* [*Absidia*] *corymbifera*, *Mucor circinelloides*, *Rhizopus arrhizus* [*Rhizopus oryzae*], and *Rhizopus microsporus*) when the number of CLSI MICs was ≥ 112 for the species/agent combination originating from ≥ 8 independent laboratories. Amphotericin B, posaconazole, and itraconazole MIC distributions comprising 10 to 93 isolates for the less prevalent species (e.g., *Apophysomyces variabilis*, *Cunninghamella bertholletiae*, *Mucor indicus*, *Mucor ramosissimus*, *Rhizomucor pusillus*, and *Syncephalastrum racemosum*) also are documented. We aggregated a total of 10 to 349 MICs (species and antifungal agent dependent) obtained in 14 independent laboratories (Argentina, Australia, Canada, Europe, India, Mexico, and the United States).

MATERIALS AND METHODS

Isolates. The isolates evaluated were recovered from patients with mostly five types of infection: rhinocerebral, pulmonary, skin, bone, cerebral (sometimes both cerebral and cutaneous or pulmonary and cutaneous), and abdominal. The most common clinical specimens were nasal or palate biopsy specimens, aspirates, swabs, or scrapes; pulmonary secretions; pleural fluids; computed tomography-guided fine-needle aspirates; and bronchoalveolar lavage and endotracheal aspirates. Antifungal susceptibility testing was performed according to the CLSI broth microdilution method (M38-A2) at the following medical centers: VCU Medical Center, Richmond, VA; Department of Medical Microbiology, Postgraduate Institute of Medical Education and Research, Chandigarh, India; Vallabhbhai Patel Chest Institute, University of Delhi, Delhi, India; Instituto Nacional de Enfermedades Infecciosas Dr. C. G. Malbrán, Buenos Aires, Argentina; Institut National de Santé Publique du Québec, Laboratoire de Santé Publique du Québec, Sainte-Anne-de-Bellevue, Québec, Canada;

University of Texas Health Science Center, San Antonio, TX; University Hospitals of Cleveland and Case Western Reserve University, Cleveland, OH; Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, México; Facultat de Medicina, IISPV, URV, Reus, Spain; National Mycology Reference Centre, SA Pathology, Adelaide, Australia; The Innsbruck Medical University, Innsbruck, Austria; Department of Medical Microbiology and Infectious Diseases, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands; Hospital General Universitario Gregorio Marañón, School of Medicine-Universidad Complutense, Madrid, Spain; and the Università degli Studi di Milano, Milan, Italy. Identification of isolates in each laboratory was performed using molecular methods or both conventional and molecular identification (5, 7, 23). Isolates were not evaluated for either azole or amphotericin B resistance mechanisms. The maximum numbers of available pooled CLSI MICs from the 14 laboratories for each species were as follows: 10 for *A. variabilis*, 32 for *C. bertholletiae*, 136 for *L. corymbifera*, 10 for *M. indicus*, 123 for *M. circinelloides*, 19 for *M. ramosissimus*, 349 for *R. arrhizus*, 146 for *R. microsporus*, 33 for *Rhizomucor pusillus*, and 36 for *S. racemosum* (Tables 1, 2, and 3). Although some laboratories submitted separate data for two varieties of *R. microsporus*, ITS sequencing of the varieties of this species has indicated that they are identical (4); therefore, we pooled all these MICs under *R. microsporus* as listed in Tables 1 to 4. Overall, these isolates represented the unique isolate recovered from each infection and were likely WT strains, but there is no information regarding the prior exposure to antifungal therapy. This could be a possible limitation of the study, as prior exposure may result in acquired antifungal resistance, skewing the results.

Three quality control (QC) strains, *Candida parapsilosis* ATCC 22019, *Candida krusei* ATCC 6258, and *Paecilomyces variotii* ATCC MYA-3630, and one reference isolate, *Aspergillus flavus* ATCC 204304, were used by the participant laboratories (12, 13).

Antifungal susceptibility testing. In order to include MIC results in the set of aggregated data from the 14 laboratories (Tables 1 to 3), amphotericin B and triazole MICs were obtained at each center by following the CLSI M38-A2 broth microdilution method (RPMI 1640 broth containing 0.2% dextrose, inoculum concentrations of $\sim 10^4$ CFU/ml, and 24 h of incubation) (12). The MICs were the lowest drug concentrations that showed 100% growth inhibition or the first clear well compared to the growth control. At least one of the three QC or reference strains were utilized during the years of testing in each center; these MICs were within the recommended MIC limits (13) with one exception. The agreement was 97% for *C. krusei* and amphotericin B (one dilution lower than established range), but the modes were within one dilution.

Definitions. The WT population is the subpopulation of isolates in a species-drug combination without detectable acquired resistance mechanisms (17). The ECV is the highest WT susceptibility endpoint; this endpoint has also been defined as the WT cutoff value (CO_{WT}).

TABLE 2 MIC distributions of posaconazole for 10 *Mucorales* species from 3 to 14 laboratories, determined by using the CLSI M38-A2 microdilution method

Species	No. of isolates tested/no. of labs	No. of isolates with MIC ($\mu\text{g/ml}$) of ^a :										
		≤ 0.03	0.06	0.125	0.25	0.5	1.0	2.0	4.0	8.0	16	32
<i>A. variabilis</i>	10/3				1	1	7	1				
<i>C. bertholletiae</i>	30/6				4	18	8					
<i>L. corymbifera</i>	112/13		3	9	26	51	21	1	1			
<i>M. circinelloides</i>	120/12		2	2	9	21	49	26	5	2	4	
<i>M. indicus</i>	10/5				2	3	3	1		1		
<i>M. ramosissimus</i>	13/4				4	4	2	2	1			
<i>R. arrhizus</i>	349/14	1	5	14	80	154	57	27	5		4	2
<i>Rhizomucor pusillus</i>	33/9		1	4	10	10	7	1				
<i>R. microsporus</i>	137/11		3	12	34	60	21	4	1		2	
<i>S. racemosum</i>	36/5	1	2	4	10	11	5	1	2			

^a The highest number in each row (showing the most frequently obtained MIC or mode) is in boldface.

In other words, the ECV is the critical drug concentration that may identify those strains with decreased susceptibility to the agent being evaluated or the non-WT isolates harboring resistant mechanisms (14, 16, 17).

Data analysis. The MIC distribution of each species-agent combination from each laboratory was listed in an Excel spreadsheet; the MIC data were reviewed for obvious outlier results and abnormalities, e.g., skewed distributions (“truncated” [mode at the lowest concentration tested] or bimodal distributions within an apparent wild type). These abnormal distributions were not included in the analysis, and outliers were not observed. Next, the presumptive WT modal MICs were determined for each species-agent combination and laboratory followed by obtaining the pooled MIC distributions for each antifungal agent and *Mucorales* species with the qualifying data. ECVs were calculated for each distribution and species by the previously reported iterative statistical technique (17). Briefly, the modeled population is based on fitting a lognormal distribution to increasing subsets of the data starting at that population that includes isolates with MICs one dilution higher than the mode (or than the lower mode if there was more than one mode) and determining the mean and standard deviation of the cumulative lognormal distribution that best fits those data; those numbers were used to calculate the MIC that captures at least 95% and 97.5% of the modeled WT population (not the observed MIC population). In addition, we evaluated the inherent variability (approximately within one doubling dilution) of susceptibility testing and the presence of outlier laboratories in each pooled distribution (24).

RESULTS AND DISCUSSION

For susceptibility testing to be useful in the clinical setting, MIC results should be reliable and must classify the infecting isolate as either resistant (nontreatable) or susceptible (treatable) to the anti-

microbial agent being evaluated (25, 26). So far, we do not have susceptibility endpoints that would allow such classification for any combination of an antifungal agent and a species belonging to the order *Mucorales*. The data needed to propose CBPs for these species and any antifungal agent are not available. However, we have gathered sufficient CLSI MICs to propose ECVs of amphotericin B and two triazoles and for four species of *Mucorales* and to provide MIC distributions for another six less prevalent species. While a total of 15 laboratories submitted MICs of amphotericin B and both triazoles, the distributions for between 1 and 2 laboratories (depending on the antifungal agent and species) were not included in the final analysis due to truncated (modal MIC at the lowest concentration tested) or bimodal (“saddle” between two modes) distributions; itraconazole data were not provided by some laboratories. In addition, several data from one of the laboratories were omitted due to the use of RPMI broth with 2% glucose (rather than 0.2% prescribed by CLSI) (12). Although some of the laboratories also submitted voriconazole data, most of the modal MICs for the different species were 16 $\mu\text{g/ml}$; the exception was the voriconazole mode of 8 $\mu\text{g/ml}$ for 235 isolates of *R. arrhizus* originating in 11 laboratories (data not shown in Tables 1 to 3).

The resulting pooled MIC distributions for the three agents and species evaluated as submitted by 3 to 14 laboratories are depicted in Tables 1 to 3. Evaluation of the pooled MIC distributions indicated that the majority of distributions for each antifungal agent and species were typical for WT organisms (3 to 5 2-fold dilution concentrations surrounding the modal MIC) and that the distributions from each laboratory were comparable as their

TABLE 3 MIC distributions of itraconazole for 7 *Mucorales* from 4 to 9 laboratories, determined by using the CLSI M38-A2 microdilution method

Species	No. of isolates tested/no. of labs	No. of isolates with MIC ($\mu\text{g/ml}$) of ^a :										
		≤ 0.03	0.06	0.125	0.25	0.5	1.0	2.0	4.0	8.0	16	32
<i>C. bertholletiae</i>	25/4				4	4	10	7				
<i>L. corymbifera</i>	93/9		5	10	24	21	23	6	3	1		
<i>M. circinelloides</i>	49/8				4	3	7	12	15	5	3	
<i>R. arrhizus</i>	215/8		4	9	40	85	37	29	2	4	5	
<i>Rhizomucor pusillus</i>	14/5			2	4	4	3	1				1
<i>R. microsporus</i>	74/6		1	1	6	15	25	20	1	1	4	
<i>S. racemosum</i>	26/5	4	3	5	7	4		1			2	

^a The highest number in each row (showing the most frequently obtained MIC or mode) is in boldface.

TABLE 4 Epidemiologic cutoff values (ECVs) for amphotericin B, posaconazole, and itraconazole and four *Mucorales* species, obtained in 8 to 14 laboratories by the CLSI M38-A2 broth microdilution method^a

Species	Antifungal agent ^b	MIC (μg/ml)		Calculated statistical ECV (μg/ml) (% of MICs above the ECV, or non-WT) ^c	
		Range	Mode ^d	≥95%	≥97.5%
<i>L. corymbifera</i>	AMB	0.06–16	0.5	1 (2.9)	2 (0.7)
	POS	0.06–4	0.5	1 (1.8)	2 (0.9)
	ITR	0.06–8	0.25	ND	ND
<i>M. circinelloides</i>	AMB	0.03–4	0.25	1 (0)	2 (0)
	POS	0.06–16	1	4 (5)	4 (5)
	ITR	0.25–16	4	ND	ND
<i>R. arrhizus</i>	AMB	0.03–4	1	2 (1.2)	4 (0)
	POS	0.03–32	0.5	1 (10.9)	2 (3.2)
	ITR	0.06–16	0.5	2 (5.1)	2 (5.1)
<i>R. microsporus</i>	AMB	0.06–4	0.5	2 (2.1)	2 (2.1)
	POS	0.06–16	0.5	1 (5.1)	2 (2.2)
	ITR	0.25–32	1	ND	ND

^a ECVs were defined only for distributions from at least three laboratories using RPMI 1640 as described in CLSI document M38-A2 (12).

^b AMB, amphotericin B; POS, posaconazole; ITR, itraconazole.

^c Calculated ECV comprising ≥95 or ≥97.5% of the statistically modeled population for each MIC distribution. ND, not determined due to insufficient numbers of laboratories and isolates/species.

^d MIC most frequently obtained for each distribution.

modal MICs for each species-agent combination were mostly within 1 2-fold dilution of one another. The exceptions were amphotericin B modes for *R. arrhizus* (modes of 0.5 to 1 μg/ml in 11 of 12 laboratories, while the mode was 0.25 μg/ml in one laboratory) and itraconazole modes for *L. corymbifera* (modes of 0.25 to 0.5 μg/ml in 8 of 9 laboratories, while the mode was 1 μg/ml in one laboratory (data not shown in Tables 1 and 3). The latter modal discrepancy accounts for the three similar “bars” observed in the pooled itraconazole and *L. corymbifera* distribution (Table 3). Amphotericin B modes were species dependent and ranged from 0.06 μg/ml (*S. racemosum*) to 2 μg/ml (*C. bertholletiae*) (Table 1). In contrast to amphotericin B, most posaconazole modes were 0.5 μg/ml; the exceptions were modes of 0.25 μg/ml (*R. pusillus*) and 1 μg/ml (*M. circinelloides* and *A. variabilis*). Physiological, genetic, and morphological data have indicated that the most clinically relevant species is *A. variabilis* (27). Data submitted for two other species in this genus (*Apophysomyces ossiformis* and *Apophysomyces trapeziformis*) were insufficient to list in Tables 1 to 3. A wider modal range (0.25 to 4 μg/ml) was observed with itraconazole, as it was for amphotericin B, among the fewer species evaluated, with the lower mode for *L. corymbifera*, *R. pusillus*, and *S. racemosum* and the highest value for *M. circinelloides*, as it was for posaconazole (Tables 2 and 3). Again, some of these distributions are small. On the whole, these results underline the need for identification to the species level as well as for antifungal susceptibility testing.

The *in vitro* activities of the three antifungal agents evaluated are similar to those previously reported for most of the species. In some instances, the pooled amphotericin B MIC ranges were wider for *L. corymbifera*, *M. circinelloides*, and *R. pusillus* than

previously reported (MIC range for the three species, 0.03 to 16 μg/ml [Table 1] versus 0.01 to 0.5 μg/ml) (19, 21, 22), but the number of isolates for these three species was lower (5 to 20 isolates) in those studies and therefore not a good representation of their susceptibility to amphotericin B. A similar discrepancy in MIC ranges was also observed with the triazole data (21, 22), but the most frequent MIC (when provided) was similar to those in the present study. In contrast, in our pooled distributions of *C. bertholletiae* (Tables 1 to 3), the highest MICs of the three agents ranged between 1 and 8 μg/ml, versus reported values of 8 to ≥64 μg/ml for sets of <7 isolates (19, 21). Based on these data and the widespread geographical area from which we received our MIC data, we surmise that the data are valid.

The CLSI has made a final decision regarding what ECV percentage (the ≥95% or the ≥97.5% value) to recommend in the CLSI document that is under development for this purpose; the lower percentage risks classifying some WT isolates as non-WT isolates, while the selected higher ECV percentage risks classifying some isolates with acquired resistance mechanisms as WT. Because of that, Table 4 depicts amphotericin B, posaconazole, and itraconazole ECVs for the aggregated distributions of four species of *Mucorales* where the data originated in 8 to 14 laboratories and comprised >100 MICs for each species and agent evaluated (using the methods that comprised ≥95% and ≥97.5% of the modeled populations). The CLSI amphotericin B ECV comprising ≥95% of the modeled populations is 1 μg/ml for *L. corymbifera* and *M. circinelloides* and 2 μg/ml for *R. arrhizus* and *R. microsporus*; however, ECVs comprising ≥97.5% of the modeled populations were one dilution higher with the exception of *R. microsporus* (both ECVs were 2 μg/ml). It is noteworthy that an amphotericin B MIC of 2 μg/ml is anecdotally considered to be the “breakpoint” for resistance and yet here and among some *Aspergillus* spp. (15) may be perceived as a WT value. The ECV of posaconazole for *L. corymbifera*, *R. arrhizus*, and *R. microsporus* is 1 μg/ml (comprising ≥95% of the modeled populations), while the ECV for *M. circinelloides* is 4 μg/ml. Posaconazole ECVs comprising ≥97.5% of the modeled populations were also one dilution higher, with the exception of the ECV of 4 μg/ml for *M. circinelloides*. Regarding itraconazole, we are proposing a 2-μg/ml ECV for *R. arrhizus*, encompassing both ≥95% and 97.5% of the modeled populations. We did not receive sufficient itraconazole data to propose ECVs for any other species or to propose amphotericin B and posaconazole ECVs for the less prevalent species. Nevertheless, the distributions for the species for which ECVs were not proposed of the three agents are depicted in Tables 1 to 3.

The frequency of amphotericin B and triazole MICs above the ECV (non-WT) varied according to the distribution analyzed (Table 4); it was lower for all species versus amphotericin B (0% to 2.9%) than for all species versus posaconazole (0.9% to 10.9%) (ECVs encompassing ≥95% and ≥97.5% of the MIC populations). As expected, the ≥95% analysis provided the highest rates of non-WT MICs: 2.9% among *L. corymbifera* versus amphotericin B and 10.9% for *R. arrhizus* and posaconazole. Acquired azole resistance in mold isolates has been studied mostly in *Aspergillus* isolates. Targeted disruption of the *cyp51A* gene in azole-susceptible *A. fumigatus* isolates has yielded strains with decreased azole susceptibility (MICs > 2 μg/ml) and a reduced concentration of intracellular drug; triazole MICs of >4 μg/ml for isolates of *Aspergillus* spp. are associated with clinical failure (28). In a similar manner, the relationship between resistance mechanisms, high

amphotericin B MICs, and clinical responses to therapy is mostly available for *Aspergillus terreus* (intrinsically resistant to this agent), *A. flavus*, and some yeast species (29, 30). On the other hand, antifungal mechanisms of resistance in the *Mucorales* are areas that deserve future investigation; to our knowledge, no information is available regarding resistance mechanisms of either amphotericin B or posaconazole in these molds despite the fact that they are the recommended therapeutic agents for mucormycosis. Despite the prolonged use of amphotericin B, its mechanisms of action and/or resistance are not completely understood; however, overall, resistance to this agent is considered rare. It is expected that mutations similar to those found in other molds could be found among non-WT isolates of the *Mucorales* versus either amphotericin B or posaconazole.

For these molds and antifungal agents, correlations between MICs and clinical response to therapy were not found in the literature, even though large numbers of mucormycosis cases have been reported. To compound the problem, cultures are not always available, since other methods of diagnosis are usually performed to promptly initiate therapy, e.g., histopathology (5, 31). Outcome is also influenced by the site of infection, the underlying disease, and other factors. However, the correlation of posaconazole MICs and treatment outcome in experimental, disseminated mucormycosis has been evaluated with a variety of *Mucorales* species. In two of these murine models, immunosuppressed animals infected with either *R. arrhizus* or *R. microsporus* isolates (posaconazole MICs, 2 µg/ml and 0.25 µg/ml for each species), survival was higher (30 to 40 versus 10 to 20%) when animals were infected with isolates with the lower MICs (32, 33). In another study, survival was strain dependent, although posaconazole MICs for both infected strains were low (0.03 and 0.12 µg/ml); however, posaconazole and amphotericin B prolonged survival among neutropenic mice infected with an isolate of *L. corymbifera* for which MICs of both agents were 0.06 to 1 µg/ml (34). According to our proposed posaconazole ECV for *L. corymbifera* and *R. microsporus*, isolates with the lower MICs and good response to treatment could be considered WT using the values that comprised ≥95% of the modeled populations; the same applies to all infective *R. arrhizus* isolates (Table 4). The response to posaconazole treatment was also found to be uncertain in two *M. circinelloides* models; efficacy was reported as good when survival was compared to that in nonimmunosuppressed control animals but variable with regard to reduction of tissue burden (35, 36). The posaconazole ECV for *M. circinelloides* is 4 µg/ml, and the isolates evaluated in those two studies could be considered either non-WT (MIC of the infecting isolate, 8 µg/ml) (35) or WT (MICs of the infecting isolates, 1 to 4 µg/ml) (36). The MIC in the first study was determined at 48 h instead of 24 h. Mechanisms of resistance were not evaluated in any of those strains, because as mentioned above, the molecular biology of the *Mucorales* is not as developed as that of *Candida* and *Aspergillus*.

In conclusion, we propose species-specific amphotericin B ECVs comprising ≥95% of the modeled populations of 1 µg/ml (*L. corymbifera* and *M. circinelloides*) to 2 µg/ml (*R. arrhizus* and *R. microsporus*), posaconazole ECVs of 1 µg/ml (*L. corymbifera*, *R. arrhizus*, and *R. microsporus*) to 4 µg/ml (*M. circinelloides*), and an itraconazole ECV of 2 µg/ml for *R. arrhizus*. ECVs were mostly one dilution higher when ≥97.5% of the modeled populations was used. Our results cover amphotericin B and its lipid formulations because their MIC data have been comparable (29). Further

studies should determine the relationship between molecular mechanisms of resistance and our proposed amphotericin B and triazole non-WT values. Although ECVs do not predict clinical response to therapy, they should be considered for inclusion in future CLSI documents regarding the setting and use of ECVs. Similar to the ECVs for *Candida* spp. and *Aspergillus* spp., the proposed ECVs for the *Mucorales* may aid in the detection of strains with acquired mechanisms of resistance (non-WT) to the agents evaluated in the present study.

REFERENCES

- Gomes MZ, Lewis RE, Kontoyiannis DP. 2011. Mucormycosis caused by unusual mucormycetes, non-*Rhizopus*, -*Mucor*, and -*Lichtheimia* species. *Clin Microbiol Rev* 24:411–445. <http://dx.doi.org/10.1128/CMR.00056-10>.
- Kwon-Chung KJ. 2012. Taxonomy of fungi causing mucormycosis and entomophthoromycosis (zygomycosis) and nomenclature of the disease: molecular mycologic perspectives. *Clin Infect Dis* 54:S8–S15. <http://dx.doi.org/10.1093/cid/cir864>.
- Skiada A, Pagano L, Groll A, Zimmerli S, Dupont B, Lagrou K, Lass-Flörl C, Bouza E, Klimko N, Gaustad P, Richardson M, Hamal P, Akova M, Meis JF, Rodriguez-Tudela JL, Roilides E, Mitrousia-Ziouva A, Petrikos G, for the European Confederation of Medical Mycology Working Group on Zygomycosis. 2011. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. *Clin Microbiol Infect* 17:1859–1867. <http://dx.doi.org/10.1111/j.1469-0691.2010.03456.x>.
- Walther G, Pawłowska J, Alastruey-Izquierdo A, Wrzosek M, Rodriguez-Tudela JL, Dolatabadi S, Chakrabarti A, de Hoog GS. 2013. DNA barcoding in *Mucorales*: an inventory of biodiversity. *Persoonia* 30:11–47. <http://dx.doi.org/10.3767/003158513X665070>.
- Cornely OA, Arikian-Akdaglı S, Dannaoui E, Groll AH, Lagrou K, Chakrabarti A, Lanternier F, Pagano L, Skiada A, Akova M, Arendrup MC, Boekhout T, Chowdhary A, Cuenca-Estrella M, Freiburger T, Guinea J, Guarro J, de Hoog S, Hope W, Johnson E, Kathuria S, Lackner M, Lass-Flörl C, Lortholary O, Meis JF, Meletiadis J, Muñoz P, Richardson M, Roilides E, Tortorano AM, Ullmann AJ, van Diepeningen A, Verweij P, Petrikos G. 2014. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. *Clin Microbiol Infect* 20(Suppl 3):5–26. <http://dx.doi.org/10.1111/1469-0691.12371>.
- Ruping MJ, Heinz WJ, Kindo AJ, Rickerts V, Lass-Flörl C, Beisel C, Herbrecht CR, Roth Y, Silling G, Ullmann AJ, Borchert K, Egerer G, Maertens J, Maschmeyer G, Simon A, Wattad M, Fischer G, Vehreschild J, Cornely OA. 2010. Forty-one recent cases of invasive zygomycosis from a global clinical registry. *J Antimicrob Chemother* 65:296–302. <http://dx.doi.org/10.1093/jac/dkp430>.
- García-Hermoso D, Dannaoui E, Lortholary O, Dromer F. 2011. Agents of systemic and subcutaneous mucormycosis and entomophthoromycosis, p 2008–2019. In Versalovic J, et al (ed), *Manual of clinical microbiology*, 10th ed. ASM Press, Washington, DC.
- Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH. 2003. Amphotericin B: time for a new “gold standard.” *Clin Infect Dis* 37:415–425. <http://dx.doi.org/10.1086/376634>.
- Pagano L, Caira M, Candoni A, Aversa F, Castagnola C, Caramatti C, Cattaneo C, Delia M, De Paolis MR, Blasi RD, Caprio LD, Fanci R, Garzia M, Martino B, Melillo L, Mitra ME, Nadali G, Nosari A, Picardi M, Potenza L, Salutari P, Trecarichi EM, Tumbarello M, Verga L, Vianelli N, Busca A, SEIFEM Group. 2012. Evaluation of the practice of antifungal prophylaxis use in patients with newly diagnosed acute myeloid leukemia: results from the SEIFEM 2010-B registry. *Clin Infect Dis* 55: 1515–1521. <http://dx.doi.org/10.1093/cid/cis773>.
- van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. 2006. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. *Clin Infect Dis* 42:e61–e65. <http://dx.doi.org/10.1086/500212>.
- Vehreschild JJ, Birtel A, Vehreschild MJT, Liss B, Farowski F, Kochanek M, Sieniawski M, Steinbach A, Wahlers K, Fätkenheuer G, Cornely OA. 2013. Mucormycosis treated with posaconazole: review of 96 case reports.

- Crit Rev Microbiol 39:310–324. <http://dx.doi.org/10.3109/1040841X.2012.711741>.
12. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi, 3rd ed. CLSI document M38-A2. Clinical and Laboratory Standards Institute, Villanova, PA.
 13. Clinical and Laboratory Standards Institute. 2012. Reference method for broth dilution antifungal susceptibility testing of yeasts; 4th informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.
 14. Espinel-Ingroff A, Pfaller MA, Bustamante B, Canton E, Fothergill A, Fuller J, Gonzalez GM, Lass-Flörl C, Lockhart SR, Martin-Mazuelos E, Meis JF, Melhem MSC, Ostrosky-Zeichner L, Pelaez T, Szeszs MW, St-Germain G, Bonfietti LX, Guarro J, Turnidge J. 2014. Multilaboratory study of epidemiological cutoff values for detection of resistance in eight *Candida* species to fluconazole, posaconazole, and voriconazole. *Antimicrob Agents Chemother* 58:2006–2012. <http://dx.doi.org/10.1128/AAC.02615-13>.
 15. Espinel-Ingroff A, Cuenca-Estrella M, Fothergill A, Fuller J, Ghannoum M, Johnson E, Pelaez T, Pfaller MA, Turnidge J. 2011. Wild-type MIC distributions and epidemiological cutoff values for amphotericin B and *Aspergillus* spp. for the CLSI broth microdilution method (M38-A2 document). *Antimicrob Agents Chemother* 55:5150–5154. <http://dx.doi.org/10.1128/AAC.00686-11>.
 16. Espinel-Ingroff A, Cuenca-Estrella M, Cantón E. 2013. EUCAST and CLSI: working together towards a harmonized method for antifungal susceptibility testing. *Curr Fungal Infect Rep* 7:59–67. <http://dx.doi.org/10.1007/s12281-012-0125-7>.
 17. Turnidge J, Kahmeter G, Kronvall G. 2006. Statistical characterization of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values. *Clin Microbiol Infect* 12:418–425. <http://dx.doi.org/10.1111/j.1469-0691.2006.01377.x>.
 18. Arikan S, Sancak B, Alp S, Hascelik G, McNicholas P. 2008. Comparative *in vitro* activities of posaconazole, voriconazole, itraconazole, and amphotericin B against *Aspergillus* and *Rhizopus*, and synergy testing for *Rhizopus*. *Med Mycol* 46:567–573. <http://dx.doi.org/10.1080/13693780801975576>.
 19. Alastruey-Izquierdo A, Castelli MV, Cuesta I, Monzon A, Cuenca-Estrella M, Rodriguez-Tudela J-L. 2009. Activity of posaconazole and other antifungal agents against *Mucorales* strains identified by sequencing of internal transcribed spacers. *Antimicrob Agents Chemother* 53:1686–1689. <http://dx.doi.org/10.1128/AAC.01467-08>.
 20. Chakrabarti A, Shivaprakash MR, Curfs-Breuker I, Baghela A, Klaassen CH, Meis JF. 2010. *Apophysomyces elegans*: epidemiology, amplified fragment length polymorphism typing, and *in vitro* antifungal susceptibility pattern. *J Clin Microbiol* 48:4580–4585. <http://dx.doi.org/10.1128/JCM.01420-10>.
 21. Vitale RG, Sybren de Hoog G, Schwarz P, Dannaoui E, Deng S, Machouart Marie Voigt K, van de Sande WWJ, Dolatabadi S, Meis JF, Walther G. 2012. Antifungal susceptibility and phylogeny of opportunistic members of the order *Mucorales*. *J Clin Microbiol* 50:66–75. <http://dx.doi.org/10.1128/JCM.06133-11>.
 22. Alastruey-Izquierdo A, Castelli MV, Cuesta I, Zaragoza O, Monzon A, Mellado E, Rodriguez-Tudela JL. 2009. *In vitro* activity of antifungals against Zygomycetes. *Clin Microbiol Infect* 15:71–76. <http://dx.doi.org/10.1111/j.1469-0691.2009.02984.x>.
 23. Halliday CL, Kidd SE, Sorrell TC, Chen SC-A. Molecular diagnostic methods for invasive fungal disease: the horizon draws nearer. *Pathology*, in press.
 24. Turnidge J, Bordash G. 2007. Statistical methods for establishing quality control limits in Clinical and Laboratory Standards Institute susceptibility testing. *Antimicrob Agents Chemother* 51:2483–2488. <http://dx.doi.org/10.1128/AAC.01457-06>.
 25. Turnidge J, Paterson DL. 2007. Setting and revising antibacterial susceptibility breakpoints. *Clin Microbiol Rev* 20:391–408. <http://dx.doi.org/10.1128/CMR.00047-06>.
 26. Dalhoff A, Ambrose PG, Mouton JW. 2009. A long journey from minimum inhibitory concentration testing to clinically predictive breakpoints: deterministic and probabilistic approaches in deriving breakpoints. *Infection* 37:296–305. <http://dx.doi.org/10.1007/s15010-009-7108-9>.
 27. Salas V, Pastor FJ, Calvo E, Sutton DA, Chander J, Mayayo E, Alvarez E, Guarro J. 2012. Efficacy of posaconazole in a murine model of disseminated infection caused by *Apophysomyces variabilis*. *J Antimicrob Chemother* 67:1712–1715. <http://dx.doi.org/10.1093/jac/dks090>.
 28. Araujo R, Espinel-Ingroff A. 2010. Antifungal resistance: cellular and molecular mechanisms. In Ahmad I, et al (ed). *Combating fungal infections: problems and remedy*. Springer, London, United Kingdom.
 29. Blum G, Hörtnagl C, Jukic E, Erbeznic T, Pümpel T, Dietrich H, Nagl M, Speth C, Rambach G, Lass-Flörl C. 2013. New insight into amphotericin B resistance in *Aspergillus terreus*. *Antimicrob Agents Chemother* 57:1583–1588. <http://dx.doi.org/10.1128/AAC.01283-12>.
 30. Lestner JM, Howard SJ, Goodwin J, Gregson L, Majithiya J, Walsh TJ, Jensen GM, Hope WW. 2010. Pharmacokinetics and pharmacodynamics of amphotericin B deoxycholate, liposomal amphotericin B, and amphotericin B lipid complex in an *in vitro* model of invasive pulmonary aspergillosis. *Antimicrob Agents Chemother* 54:3432–3441. <http://dx.doi.org/10.1128/AAC.01586-09>.
 31. Petrikos G, Skiada A, Drogari-Apiranthitou M. 2014. Epidemiology of mucormycosis in Europe. *Clin Microbiol Infect* 20:67–73. <http://dx.doi.org/10.1111/1469-0691.12563>.
 32. Rodríguez MM, Pastor JF, Sutton DA, Calvo E, Fothergill AW, Salas V, Rinaldi MG, Guarro J. 2010. Correlation between *in vitro* activity of posaconazole and *in vivo* efficacy against *Rhizopus oryzae* infection in mice. *Antimicrob Agents Chemother* 54:1665–1669. <http://dx.doi.org/10.1128/AAC.01463-09>.
 33. Rodríguez MM, F. Pastor JF, Calvo E, Salas V, Sutton DA, Guarro J. 2009. Correlation of *in vitro* activity, serum levels, and *in vivo* efficacy of posaconazole against *Rhizopus microsporus* in a murine disseminated infection. *Antimicrob Agents Chemother* 53:5022–5025. <http://dx.doi.org/10.1128/AAC.01026-09>.
 34. Spreghini E, Orlando F, Giannini D, Barchiesi F. 2010. *In vitro* and *in vivo* activities of posaconazole against zygomycetes with various degrees of susceptibility. *J Antimicrob Chemother* 65:2158–2163. <http://dx.doi.org/10.1093/jac/dkq276>.
 35. Sun QN, Najvar LK, Bocanegra R, Loebenberg D, Graybill JR. 2002. *In vivo* activity of posaconazole against *Mucor* spp. in an immunosuppressed-mouse model. *Antimicrob Agents Chemother* 46:2310–2312. <http://dx.doi.org/10.1128/AAC.46.7.2310-2312.2002>.
 36. Salas V, Pastor FJ, Calvo E, Alvarez E, Sutton DA, Mayayo E, Fothergill AW, Rinaldi MG, Guarro J. 2012. *In vitro* and *in vivo* activities of posaconazole and amphotericin B in a murine invasive infection by *Mucor circinelloides*: poor efficacy of posaconazole. *Antimicrob Agents Chemother* 56:2246–2250. <http://dx.doi.org/10.1128/AAC.05956-11>.